Interestingly, remitters showed greater CRP reductions, and CRP variation correlated with baseline depression severity, supporting the contribution of an inflammatory component to treatment response and the possibility that agomelatine's improvement in anhedonia could be linked, at least in part, to modulating inflammatory pathways. The gene discussed is CRP; the disease is depressive disorder.